Article
A review of nateglinide in the management of patients with type 2 diabetes.
Vascular health and risk management - 1 Jan 2007
Tentolouris Nicholas, Voulgari Christina, Katsilambros Nicholas
Abstract excerpt
Impaired insulin secretion occurs early in the pathogenesis of type 2 diabetes mellitus (T2DM) and is chronic and progressive, resulting initially in impaired glucose tolerance (IGT) and eventually in T2DM. As most patients with T2DM have both insulin resistance and insulin deficiency, therapy for T2DM should aim to control not only fasting, but also postprandial plasma glucose levels. While oral glucose-lowering...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.